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FALSE-POSITIVE METHADONE URINE DRUG SCREEN IN 
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SUMMARY – We present a case of T.M. admitted to University Department of Psychiatry, 
Split University Hospital Center, in Croatia, because of the acute psychotic reaction (F23.9). The 
patient’s urine tested positive for methadone without a history of methadone ingestion. Urine drug 
screen was performed with the COBAS Integra Methadone II test kit (kinetic interaction of micro-
particles in solution /KIMS/ methodology) by Roche. Drugs that have been shown to cross-react 
with methadone feature a tricyclic structure with a sulfur and nitrogen atom in the middle ring, 
which is common for both quetiapine and methadone. Therefore, it is plausible that this structu-
ral similarity between quetiapine and methadone could underlie the cross-reactivity on methadone 
drug screen. Besides quetiapine, a number of routinely prescribed medications have been associated 
with triggering false-positive urine drug screen results. Verification of the test results with a diffe-
rent screening test or additional analytical tests should be performed to avoid adverse consequences 
for the patients.
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Introduction
Quetiapine is a dibenzothiazepine atypical antip-
sychotic. It has been proposed that this drug’s antip-
sychotic activity is mediated through a combination of 
dopamine type 2 (D2) and serotonin type 2 (5-HT2) 
antagonism. It is an antagonist at multiple neurotrans-
mitter receptors in the brain: serotonin 5-HT1A and 
5-HT2, dopamine D1 and D2, histamine H1, and 
adrenergic alpha1- and alpha2-receptors, but appears 
to have no appreciable affinity at cholinergic muscar-
inic and benzodiazepine receptors. Norquetiapine, an 
active metabolite, differs from its parent molecule by 
exhibiting high affinity for muscarinic M1 receptors1.
Methadone is a synthetic opioid, used medically 
as an analgesic and a maintenance anti-addictive for 
use in patients with opioid dependency. It was devel-
oped in Germany in 1937. Although chemically un-
like morphine or heroin, methadone acts on the same 
opioid receptors as these drugs, and thus has many of 
the same effects. Methadone is also used in manag-
ing severe chronic pain, owing to its long duration of 
action, extremely powerful effects, and very low cost. 
Methadone is a partial µ-opioid agonist. Methadone 
also binds to the glutamatergic NMDA (N-methyl-
D-aspartate) receptor, and thus acts as a receptor an-
tagonist against glutamate1.
Drug screening through urinalysis is a widely ac-
cepted method for rapid detection of the potential 
drug abuse. The most commonly used tests to screen 
urine for drugs of abuse are immunoassays, even 
though false-positive results for drugs of abuse have 
been reported with a number of these rapid-screening 
products2. Confirmation of presumptive positive urine 
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drug screens, necessary to minimize the reporting of 
false-positive results, can be costly and time-consum-
ing3.
Interference in immunoassay is one of the factors 
that contribute to the uncertainty of medical testing. 
Cross-reactivity has been reported in the methods of 
drug misuse screening4. Cross-reactivity is the most 
common interference in immunoassays, but mostly 
in competitive ones. It is a nonspecific influence of 
substances in a sample that structurally resembles the 
analyte (carries similar or the same epitopes like the 
analyte) and competes for the binding site on the an-
tibody5. The interference grade caused by cross-reac-
tivity depends on three factors: antibody specificity, 
method, and sample preparation6. Cross-reactivity of 
structurally similar substances is a problem associated 
with immunoassay methodologies, resulting in false-
positive or false-negative results. Screening tech-
nologies are predominantly immunoassay techniques 
which may prove high sensitivity but are of limited 
specificity.
In immunoassays, an antibody used as a reagent 
detects the analyte (antigen) of interest. Although 
the noncovalent bond between the analyte and the 
complementary antibody is specific, false-positive and 
false-negative interferences are possible. Some inter-
ferences are similar to those in chemical analyses and 
some are typical only for immunoassays. One should 
suspect interferences in the following cases: upon re-
ceiving an unacceptable result, if there is non-linearity 
during dilution, if there is no agreement with other 
test results or clinical data, or if different immuno-
assays in determination of the same analyte provide 
significantly different results4.
Drugs that have been shown to cross-react with 
methadone feature a tricyclic structure with a sulfur 
and nitrogen atom in the middle ring, which is com-
mon to both quetiapine and methadone. Therefore, 
it is plausible that this structural similarity between 
quetiapine and methadone could underlie cross-reac-
tivity on methadone drug screen. Besides quetiapine, 
a number of routinely prescribed medications have 
been associated with triggering false-positive urine 
drug screen results.
We present a case of T.M., admitted to the De-
partment of Psychiatry, Split University Hospital 
Center, in Croatia, because of the acute psychotic re-
action (F23). Urine sample obtained from the patient 
tested positive for methadone without a history of 
methadone ingestion.
Urine drug screen was performed with the COBAS 
INTEGRA Methadone II test kit (kinetic interaction 
of microparticles in solution /KIMS/ methodology) 
by Roche. The COBAS INTEGRA Methadone II 
assay is based on the kinetic interaction of micropar-
ticles in a solution (KIMS) as measured by changes 
in light transmission. In the absence of sample drug, 
soluble drug polymer conjugates bind to antibody-
bound microparticles, causing the formation of par-
ticle aggregates.
When a urine sample containing the drug in 
question is present, this drug competes with the 
conjugate-bound drug derivative for microparticle-
bound antibody. Antibody bound to sample drug is 
no longer available to promote particle aggregation, 
and subsequent particle lattice formation is inhibited. 
As the aggregation reaction proceeds in the absence 
of sample drug, the absorbance increases. Conversely, 
the presence of sample drug diminishes the increasing 
absorbance in proportion to the concentration of drug 
in the sample. Sample drug content is determined 
relative to the value obtained for a known cutoff con-
centration of drug7,8.
Case Report
We report a case of T.M., a 30-year-old male pa-
tient, who was admitted to University Department of 
Psychiatry, Split University Hospital Center in Split, 
Croatia, for acute psychotic exacerbation (F 23.9), 
paranoid-hallucinatory features. The patient had ex-
perienced the first psychotic episode two months be-
fore and the episode we report was his second exac-
erbation. 
Table 1. Reports of false-positive results of urine drug 
screens for commonly used antipsychotics
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During the examination, the patient stated that 
he had consumed different psychostimulative drugs 
of abuse (amphetamines) several days before hospital 
admission. Therefore, as part of the routine laboratory 
diagnostic work-up, the urine drug screen was made, 
which showed a positive amphetamine result.
We started antipsychotic treatment with quetiap-
ine (900 mg/24 h) and risperidone (6 mg/24 h) and 
achieved substantial improvement within 2 weeks. 
Two weeks after admission, as part of the routine 
laboratory diagnostic work-up, the urine drug screen 
was repeated and showed methadone-positive result. 
Since the patient was persistently denying consump-
tion of any drugs of abuse during his hospital stay, 
and because of the internal organization of the De-
partment, it was not possible to come in contact with 
drugs of abuse, the urine drug screen result was inter-
preted as false-positive. 
In fact, because of the structural similarity be-
tween quetiapine and methadone, the guidelines 
of the urine drug screen test kit used (COBAS IN-
TEGRA Methadone II test kit, Roche Diagnostics; 
semiquantitive detection) admit the possible cross-
reactivity with quetiapine. 
The additional test with gas chromatography (GC) 
was performed to exclude methadone abuse.
Discussion
Awareness of the potential for false-positive re-
sults and confirmatory follow-up information are 
particularly important for both the clinicians and the 
patients because the false-positive urine drug screen 
results may affect the clinician-patient relationship by 
raising issues of trust.
Reports of false-positive results were found for the 
following formulary and nonprescription medications: 
brompheniramine, bupropion, chlorpromazine, clomip-
ramine, dextromethorphan, diphenhydramine, doxy-
lamine, ibuprofen, naproxen, promethazine, quetiapine, 
quinolones (ofloxacin and gatifloxacin), ranitidine, ser-
traline, thioridazine, trazodone, venlafaxine, verapamil, 
and for the nonprescription nasal inhaler. False-positive 
results for amphetamine and methamphetamine were 
most commonly reported. False-positive results for 
methadone, opioids, phencyclidine, barbiturates, can-
nabinoids, and benzodiazepines were also reported in 
patients taking commonly used medications2.
Drugs that have been shown to cross-react with 
methadone feature a tricyclic structure with a sulfur 
and nitrogen atom in the middle ring, which is com-
mon to both quetiapine and methadone. Therefore, 
it is plausible that this structural similarity between 
quetiapine and methadone could underlie cross-reac-
tivity on methadone drug screen.
Several authors have reported cases of patients 
treated with quetiapine who showed methadone-pos-
itive urine drug screens9-11. 
Besides quetiapine, a number of routinely pre-
scribed medications have been associated with trig-
gering false-positive urine drug screen results. Verifi-
cation of test results with a different screening test or 
additional analytical tests such as high-performance 
liquid chromatography or liquid chromatography-
mass spectrometry should be performed to avoid ad-
verse consequences for the patients12.
Processes need to be in place to make both labo-
ratories and physicians aware of the potential for im-
munoassay interference, which can lead to clinical 
misinterpretation. The processes include on-going 
education, review of patient results in the clinical set-
ting, protocols for testing of suspected interference, 
and notification of interferences both to the physician 
and to the diagnostic manufacturer. To minimize the 
reporting of false-positive or false-negative results, a 
constant dialogue is required between physician and 
laboratory about unexpected immunoassay results13,14.
Conclusion
Drug screening through urinalysis is a widely ac-
cepted method for rapid detection of the potential 
drug abuse. Cross-reactivity of structurally similar 
substances is a problem associated with immunoas-
say methodologies, resulting in false-positive or false-
negative results. Verification of test results with a 
different screening test or additional analytical tests 
should be performed to avoid adverse consequences 
for the patients. To minimize the reporting of false-
positive or false-negative results, a constant dialogue 
is required between physician and laboratory about 
unexpected immunoassay results. It is recommended 
to review patient results in the clinical setting, proto-
cols for testing of suspected interference, and notifica-
tion of interferences both to the physician and to the 
diagnostic manufacturer.
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Sažetak
LAŽNO POZITIVNI NALAZ METADONA U MOKRAĆI BOLESNIKA LIJEČENOG KVETIAPINOM
D. Lasić, B. Uglešić, M. Žuljan-Cvitanović, D. Šupe-Domić i L. Uglešić
Testovi probira mokraće široko su prihvaćena metoda brzog otkrivanja moguće zloporabe psihoaktivnih supstanca. 
Najčešće korišteni testovi analize mokraće na droge su imunokemijske metode, unatoč činjenici da su prijavljeni brojni 
slučajevi lažno-pozitivnih rezultata za mnoge od testova za brzo otkrivanje. Potvrda mogućih pozitivnih probira mokraće 
na lijekove, koja je neophodna kako bi se smanjio broj prijava lažno pozitivnih rezultata, može biti skupa i zahtijevati veći 
utrošak vremena za analizu. Prikazuje se slučaj bolesnika T.M. zaprimljenog u Kliniku za psihijatriju Kliničkog bolničkog 
centra Split poradi akutne psihotične reakcije (F23). U mokraći bolesnika testiranog na metadon isti je otkriven, ali bez 
potvrde konzumacije istog. Analiza mokraće provedena je testom COBAS Integra Methadone II (kinetička interakcija 
mikročestica u otopini, metoda KIMS) tvrtke Roche. Lijekovi koji su pokazali križnu reaktivnost s metadonom sadrže 
tricikličnu strukturu s atomima sumpora i dušika u srednjem prstenu, što je zajedničko i kvetiapinu i metadonu. Stoga je 
za pretpostaviti da je strukturna sličnost kvetiapina i metadona uzrokom križne reaktivnosti u testu probira na metadon. 
Uz kvetiapin, velik broj rutinski propisivanih lijekova pokazao je povezanost s pojavom lažno-pozitivnih rezultata u testo-
vima mokraće. Kako bi se izbjegle neželjene posljedice za bolesnike potrebna je verifikacija rezultata dodatnim metodama 
potvrde.
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